{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:05:18Z","timestamp":1789473918174,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102656","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:20:01Z","timestamp":1787926801000},"page":"102656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Value of Bayesian Statistics in Prostate Cancer Research: A Clinician-Oriented Review"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-8446","authenticated-orcid":false,"given":"Shugo","family":"Yajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102656_bib0001","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/pst.2192","article-title":"Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan","volume":"21","author":"Hirakawa","year":"2022","journal-title":"Pharm Stat"},{"key":"10.1016\/j.clgc.2026.102656_bib0002","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/2168479017728989","article-title":"Utility of Bayesian single-arm design in new drug application for rare cancers in Japan: a case study of phase 2 trial for sarcoma","volume":"52","author":"Hirakawa","year":"2018","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.clgc.2026.102656_bib0003","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s43441-023-00515-3","article-title":"A tutorial on modern Bayesian methods in clinical trials","volume":"57","author":"Muehlemann","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.clgc.2026.102656_bib0004","doi-asserted-by":"crossref","DOI":"10.62675\/2965-2774.20250267","article-title":"Understanding Bayesian analysis of clinical trials: an overview for clinicians","volume":"37","author":"Taylor","year":"2025","journal-title":"Crit Care Sci"},{"key":"10.1016\/j.clgc.2026.102656_bib0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jtho.2020.10.010","article-title":"Principles and reporting of Bayesian trials","volume":"16","author":"Lee","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.clgc.2026.102656_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014A scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"10.1016\/j.clgc.2026.102656_bib0007","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102656_bib0008","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1541-0420.2012.01823.x","article-title":"Real-time individual predictions of prostate cancer recurrence using joint models","volume":"69","author":"Taylor","year":"2013","journal-title":"Biometrics"},{"key":"10.1016\/j.clgc.2026.102656_bib0009","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12874-017-0382-9","article-title":"Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer","volume":"17","author":"Desm\u00e9e","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clgc.2026.102656_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102656_bib0011","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bju.15136","article-title":"Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance","volume":"127","author":"Tomer","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102656_bib0012","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11523-025-01148-2","article-title":"A Bayesian network meta-analysis of systemic treatments for metastatic castration-resistant prostate cancer in first- and subsequent lines","volume":"20","author":"Wosny","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.clgc.2026.102656_bib0013","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","article-title":"Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102656_bib0014","article-title":"Comparison of PET\/CT and MRI in the diagnosis of bone metastasis in prostate cancer patients: a network analysis of diagnostic studies","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102656_bib0015","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.clgc.2026.102656_bib0016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euo.2023.01.009","article-title":"Safety and efficacy of salvage stereotactic radiation therapy in patients with intraprostatic tumor recurrence after previous external radiation therapy: phase 1 results from the GETUG-AFU 31 study","volume":"6","author":"Pasquier","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102656_bib0017","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/1078-0432.CCR-23-2585","article-title":"Backfilling patients in phase I dose-escalation trials using Bayesian optimal interval design (BOIN)","volume":"30","author":"Zhao","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102656_bib0018","first-page":"627","article-title":"BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials","volume":"8","author":"Yuan","year":"2021","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.clgc.2026.102656_bib0019","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1007\/s00259-026-07956-6","article-title":"PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer","volume":"53","author":"Zuur","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clgc.2026.102656_bib0020","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102656_bib0021","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/psp4.12914","article-title":"Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of ^177^Lu-PSMA-617 in prostate cancer patients","volume":"12","author":"Siebinga","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clgc.2026.102656_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40658-024-00642-2","article-title":"Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic\/pharmacodynamic model","volume":"11","author":"Siebinga","year":"2024","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.clgc.2026.102656_bib0023","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/psp4.12812","article-title":"Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I","volume":"11","author":"Margossian","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clgc.2026.102656_bib0024","article-title":"Identifying confounders using Bayesian networks and estimating treatment effect in prostate cancer with observational data","volume":"7","author":"Sieswerda","year":"2023","journal-title":"JCO Clin Cancer Inform"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:35:26Z","timestamp":1789472126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"alternative-id":["S1558767326001564"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102656","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Value of Bayesian Statistics in Prostate Cancer Research: A Clinician-Oriented Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102656"}}